Angiotech Pharmaceuticals, Inc. Announces Financial Results for the Fourth Quarter Ended December 31, 2012
VANCOUVER, March 28, 2013 /PRNewswire/ - Angiotech Pharmaceuticals, Inc.
("Angiotech") announced that it released its financial results for the
fourth quarter ended December 31, 2012.
Selected recent developments and highlights include:
* Sale of Interventional Products Business to Argon Medical Devices, Inc. On March 25, 2013, we announced that we entered into a definitive agreement to sell certain of our subsidiaries, comprising Angiotech's Interventional Products Business to Argon Medical Devices, Inc., a Delaware corporation ("Argon"), which is a portfolio company of RoundTable, for $362.5 million in cash consideration.
Selected recent developments and highlights include:
* Sale of Interventional Products Business to Argon Medical Devices, Inc. On March 25, 2013, we announced that we entered into a definitive agreement to sell certain of our subsidiaries, comprising Angiotech's Interventional Products Business to Argon Medical Devices, Inc., a Delaware corporation ("Argon"), which is a portfolio company of RoundTable, for $362.5 million in cash consideration.